New Understanding of the Mechanism of the Carcinoid Flush
Authors: Dean T. Mason, Kenneth L. Melmon
Journal: Annals of Internal Medicine (1966)

Editorials1 December 1966New Understanding of the Mechanism of the Carcinoid FlushDEAN T. MASON, M.D., KENNETH L. MELMON, M.D.DEAN T. MASON, M.D., KENNETH L. MELMON, M.D.Author, Article, and Disclosure Informationhttps://doi.org/10.7326/0003-4819-65-6-1334 SectionsAboutPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail ExcerptAlthough it is now well established that an overproduction of serotonin (5-hydroxytryptamine) consistently attends the carcinoid syndrome, attention has recently been focused on the elaboration of other physiologically active substances in patients with carcinoid tumors. A variety of clinical and pathologic features distinct from those ordinarily associated with the ileal carcinoid tumor have been described, and the importance attributed to serotonin as the sole mediator of carcinoid symptomatology has been challenged (1-5). Thus, the carcinoid tumor may possess multiple endocrine properties capable of producing a spectrum of clinical conditions rather than a single syndrome. Indeed, elevated excretions of urinary histamine,...References1. ROBERTSONPEARTANDREWS JIWSTM: The mechanism of facial flushes in the carcinoid syndrome. Quart. J. Med. 31: 103, 1962. MedlineGoogle Scholar2. LEVINESJOERDSMA RJA: Pressor amines and the carcinoid flush. Ann. Intern Med. 58: 818, 1963. LinkGoogle Scholar3. OATESMELMONSJOERDSMAGILLESPIEMASON JAKALDT: Release of a kinin peptide in the carcinoid syndrome. Lancet 1: 514, 1964. CrossrefMedlineGoogle Scholar4. SJOERDSMAMELMON AK: The carcinoid spectrum. Gastroenterology 47: 104, 1964. MedlineGoogle Scholar5. MELMONSJOERDSMAMASON KLADT: Distinctive clinical and therapeutic aspects of the syndrome associated with bronchial carcinoid tumors. Amer. J. Med. 39: 568, 1965. CrossrefMedlineGoogle Scholar6. PENNOWWALDENSTROM BJ: Determination of 5-hydroxytryptamine, 5-hydroxyindole acetic acid and histamine in thirty-three cases of carcinoid tumor (Argentaffinoma). Amer. J. Med. 23: 16, 1957. CrossrefMedlineGoogle Scholar7. OATESSJOERDSMA JAA: A unique syndrome associated with secretion of 5-hydroxytryptophan by metastatic gastric carcinoids. Amer. J. Med. 32: 333, 1962. CrossrefMedlineGoogle Scholar8. SCHNECKLOTHPAGEDEL GRECOCORCORAN RIHFAC: Effects of serotonin antagonists in normal subjects and in patients with carcinoid tumors. Circulation 16: 523, 1957. CrossrefMedlineGoogle Scholar9. HILTONLEWIS SMGP: The relationship between glandular activity, bradykinin formation and functional vasodilatation in the submandibular salivary gland. J. Physiol. (London) 134: 471, 1956. CrossrefGoogle Scholar10. MASONMELMON DTKL: Effects of bradykinin on forearm venous tone and vascular resistance in man. Circ. Res. 17: 106, 1965. CrossrefMedlineGoogle Scholar11. MELMONLOVENBERGSJOERDSMA KLWA: Characteristics of carcinoid tumor kallikrein: identification of lysyl-bradykinin as a peptide it produces in vitro. Clin. Chim. Acta 12: 292, 1965. CrossrefGoogle Scholar12. WEBSTERPIERCE MEJV: The nature of the kallidins released from human plasma by kallikreins and other enzymes. Ann. N. Y. Acad. Sci. 104: 91, 1963. CrossrefMedlineGoogle Scholar13. OATESPETTINGERDOCTOR JAWARB: Evidence for the release of bradykinin in carcinoid syndrome. J. Clin. Invest. 45: 173, 1966. CrossrefMedlineGoogle Scholar14. MASONMELMON DTKL: Abnormal forearm vascular responses in the carcinoid syndrome: the role of kinins and kinin generating system. J. Clin. Invest. 45: 1685, 1966. CrossrefMedlineGoogle Scholar15. HOLDSTOCKMATHIASSCHACHTER DJAPA: A comparative study of kinin, kallidin, and bradykinin. Brit. J. Pharmacol. 12: 149, 1957. Google Scholar This content is PDF only. To continue reading please click on the PDF icon. Author, Article, and Disclosure InformationAffiliations: PreviousarticleNextarticle Advertisement FiguresReferencesRelatedDetails Metrics Cited byCarcinoid Crisis: History, Dogmas, and DataΒ-Adrenergic agonist administration is not associated with secondary carcinoid crisis in patients with carcinoid tumorA prospective study of the pathophysiology of carcinoid crisisSkin Manifestations of Internal MalignancyBlushing and social phobia: a neuroethological speculationClinical Applications of Gastrointestinal HormonesBiology and management of the midgut carcinoidThe butterfly rash and the malar flushTissue HormonesMetastatic cutaneous carcinoidGewebehormoneFacial Flushing Is Not BlushingCarcinoid SyndromeTissue HormonesCarcinoid tumorsThe Carcinoid Syndrome: Chronic Treatment with Para-ChlorophenylalanineWINSTON G. SATTERLEE, M.D., ARTHUR SERPICK, M.D., F.A.C.P., JOSEPH R. BIANCHINE, Ph.D., M.D.Twenty years of gastrointestinal carcinoidsEvaluation of the Role of Kinins in Experimental, Pathological, and Clinical Conditions; the Therapeutic Use of Kallikrein InhibitorMassive hepatic resection for the carcinoid syndromeInsulin-secreting bronchial carcinoid tumor with widespread metastasesThe carcinoid syndromeCase 7-1968Ophthalmic Manifestations of the Carcinoid Flush 1 December 1966Volume 65, Issue 6Page: 1334-1339KeywordsCarcinoid tumorExcretionHistamineResearch grantsSerotonin Issue Published: 1 December 1966 PDF downloadLoading ...